Skip to main content
SpringerLink
Log in

In a recent report, Decision Resources suggests that second-line patient share of monoamine oxidase B (MAO B) inhibitors has increased

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Decision Resources Inc.Teva's Azilect Use Dramatically Increases in Second-Line Therapy for the Treatment of Parkinson's Disease. Media Release: 4 Mar 2009. Available from: URL: http://www.decisionresources.com

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

In a recent report, Decision Resources suggests that second-line patient share of monoamine oxidase B (MAO B) inhibitors has increased. Pharmacoecon. Outcomes News 574, 7 (2009). https://doi.org/10.2165/00151234-200905740-00016

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200905740-00016

Keywords

Search

Navigation